Atai Life Sciences: Positive BPL-003 Data In AUD Leads To Another Catalyst
Atai Life Sciences N.V. reported positive top-line phase 2a results of BPL-003 in treating Alcohol Use Disorder patients.
Psychedelic: atai Life Sciences reports BPL-003 study results
In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on study results, an analyst ...
BPL-003 shows promise in alcohol use disorder study
NEW YORK and BERLIN - atai Life Sciences (NASDAQ: ATAI), a biopharmaceutical company focused on mental health treatments with a current market capitalization of $243 million, announced positive ...
Atai Life Sciences announces results from BPL-003 Phase 2a open-label study
Life Sciences (ATAI) announced topline results from Beckley Psytech’s Phase 2a open-label study of BPL-003 in 12 patients with moderate to ...
BioSpace3d
GH’s Inhaled Psychedelic Succeeds in Mid-Stage Depression Trial
In a Phase IIb trial, GH001 elicited significant drops in treatment-resistant depression. The news comes less than two weeks ...
Atai reports positive data for psychedelic drug BPL-003
Atai Life Sciences (NASDAQ:ATAI) reported positive topline results from a Phase 2a study of the psychedelic drug BPL-003 in the treatment of patients with moderate to severe alcohol use disorder, or ...
pharmaphorum10d
Beckley builds case for its psychedelic depression therapy
The results come from a phase 2a study of BPL-003, a novel formulation of 5-MeO-DMT (sometimes called mebufotenin), which is a psychoactive compound found in a wide variety of plant species ...
Enid News & Eagle10d
atai Life Sciences Announces Positive Topline Results from Beckley Psytech’s BPL-003 ...
A single dose of BPL-003, combined with relapse prevention therapy, produced meaningful and sustained reductions in alcohol use, with 50% of patients maintaining complete abstinence out to three ...
BioSpace8d
Atai Touts Positive Data for Psychedelic Therapy in Alcohol Use Disorder
The results, which come on the heels of the FDA’s approval of J&J’s esketamine nasal spray Spravato as a monotherapy for ...
pharmaphorum11d
atai invests $50m in Beckley Psytech
Specifically, the financing will support Beckley Psytech in advancing BPL-003, a novel intranasal formulation of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT, or Mebufotenin) that is currently ...
Atai Life Sciences And 2 Other Promising Penny Stocks On US Exchanges
As the U.S. stock market navigates a week of fluctuating earnings reports and economic indicators, investors are keenly observing opportunities across various sectors. Penny stocks, often associated ...
Yahoo Finance6d
Atai Life Sciences N.V. (ATAI)
A single dose of BPL-003, combined with relapse prevention therapy, produced meaningful and sustained reductions in alcohol use, with 50% of patients maintaining complete abstinence out to three ...